Trials / Active Not Recruiting
Active Not RecruitingNCT02446405
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,125 (actual)
- Sponsor
- University of Sydney · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | |
| DRUG | NSAA | |
| DRUG | LHRHA or Surgical Castration |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
- First posted
- 2015-05-18
- Last updated
- 2025-02-06
Locations
82 sites across 6 countries: United States, Australia, Canada, Ireland, New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT02446405. Inclusion in this directory is not an endorsement.